HPV Prevalence in Colombian Women with Cervical Cancer: Implications for Vaccination in a Developing Country

Table 4

Impact of HPV vaccines according to age specific HPV prevalence.

(a) Cervical cancer incident cases

Country	Group of age			Total*
	<50	50–59	≥60
Colombia, Cali	489	217	339	1045
Uganda, Kyadondo County	313	69	70	452
USA, Connecticut	382	52	46	480

(b) Expected incident cases and estimated impact of vaccination

Case	<50	50–59	≥60	Impact based on global estimates	Impact based on age-specific estimates
HPV 16,18
Attributable cases (%)	65.5	77.1	46.3	63.2	—
Colombia, Cali	169	50	182	63.2	61.7
Uganda, Kyadondo County	108	16	38	63.2	64.3
USA, Connecticut	132	12	25	63.2	64.9
HPV 16,18,45
Attributable cases (%)	79.8	79.4	48.6	71.4	—
Colombia, Cali	99	45	174	71.4	69.6
Uganda, Kyadondo County	63	14	36	71.4	74.9
USA, Connecticut	77	11	24	71.4	76.8
HPV 16,18,45,31
Attributable cases (%)	85.2	80.6	58.4	76.8	—
Colombia, Cali	72	42	141	76.8	75.6
Uganda, Kyadondo County	46	13	29	76.8	80.3
USA, Connecticut	57	10	19	76.8	82.1
HPV 16,18,45,58
Attributable cases (%)	81.6	87.4	60.6	77.3	—
Colombia, Cali	90	27	134	77.3	76.0
Uganda, Kyadondo County	58	9	28	77.3	79.2
USA, Connecticut	70	7	18	77.3	80.2

Incident cases in (a) based on 28. Attributable cases based on study results. Numbers for each country in (b) correspond to the expected number of cases given the percentage of attributable cases. The impact based on global estimates was obtained from cumulative percentages in Figure 1(a). The impact based on age-specific estimates corresponds to the reduction in number of cases as percentage of the initial number of cases, obtained from the summatory of expected cases in age groups (<50, 50–59, ≥60). Single infections assumed after distribution of multiple infections.
*Total cases do not include unknown age.